Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | DUT | P33316 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31647790 | 0.83 | TDP1 (0.48) | TDP1DUTMEN1KMT2A | |
| SCHEMBL19460463 | 0.80 | DUT (0.38) | DUT | |
| SCHEMBL9989980 | 0.79 | GPR84 (0.43) | DUT | |
| SCHEMBL9989984 | 0.79 | GPR84 (0.43) | DUT | |
| SCHEMBL19460464 | 0.78 | DUT (0.39) | DUT | |
| SCHEMBL28580283 | 0.78 | GSR (0.43) | MEN1KMT2A | |
| SCHEMBL29767917 | 0.77 | SMN1; SMN2 (0.33) | DUTMEN1KMT2A | |
| SCHEMBL7365588 | 0.75 | DUT (0.33) | DUTMEN1KMT2A | |
| SCHEMBL9627836 | 0.75 | ZDHHC7 (0.36) | DUT | |
| SCHEMBL23067127 | 0.75 | LMNA (0.38) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030027870-A1 | Fullerene derivatives that modulate nitric oxide synthase and clamodulin activity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027870-A1 | Fullerene derivatives that modulate nitric oxide synthase and clamodulin activity | NOS1, NOS2, NOS3 | TDP1 1106/4885DUT 3314/4885MEN1 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.